-
Pharmacodynamic Analysis of AGAVE-201 Indicates Changes in CSF-1R–Expressing Cells and Associated Biomarkers Potentially Contributing to Chronic Graft-Versus-Host Disease Resolution
-
Clinical and Disease Characteristics of Initial Participants at Time of Enrollment in THRIVE, a Prospective, Observational Cohort Study of Patients at Risk for Chronic Graft Versus Host Disease
-
CSF1R-CSF1 Axis Blockade with Axatilimab Effectively Targets Leukemia Stem Cells and Monocytes in AML Resistant to BH3 Mimetics
-
Safety Analysis of Axatilimab in Patients With Chronic Graft-Versus-Host Disease in an Expanded Access Program
-
Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML
-
Trial in Progress: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Moderate to Severe Chronic Graft-Versus-Host Disease
-
Safety and Feasibility of 0.6 mg/kg Every 4 Weeks Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study
-
2002 Pivotal Phase 2 Results of AUGMENT-101 for Revumenib in KMT2Ar Acute Leukemia: Pediatric Experience
-
D18 Revumenib Monotherapy in Patients With Relapsed/Refractory KMT2Ar Acute Leukemia: Efficacy and Safety Results From the AUGMENT-101 Phase 1/2 Study
-
Safety and Activity of Revumenib in Combination With Fludarabine/Cytarabine (FLA) in Patients With Relapsed/Refractory Acute Leukemias
-
Characterization of Immunophenotypic Changes Following Menin Inhibition in Acute Myeloid Leukemia
-
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study
-
Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium
-
157 Pharmacokinetics and Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients with Relapsed/Refractory Acute Leukemias
-
C075 Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study
-
Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias
-
Revumenib Physiologically Based Pharmacokinetic (PBPK) Model for Evaluation of Age Effect and CYP3A4-mediated Drug-Drug Interaction (DDI) in Relapsed /Refractory Acute Leukemias
-
Revumenib as Pre-Emptive Therapy for Measurable Residual Disease in NPM1-mutated or KMT2A-rearranged AML: a Domain of the Multi-Arm ALLG AMLM26 INTERCEPT Platform Trial
-
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
-
Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
-
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib: Trial in Progress
-
Characterization of acquired resistance mutations to menin inhibitors
-
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study
-
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Efficacy and Safety Results from the AUGMENT-101 Phase 1/2 Study
-
Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
-
Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
-
Safety, Tolerability, and Efficacy of Axatilimab, a Colony-Stimulating Factor 1 Receptor (CSF-1R) Humanized Antibody, in Advanced Chronic Graft-versus-host Disease-Related Bronchiolitis Obliterans Syndrome
-
Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
-
Single-Cell Transcriptomic Studies Reveal Altered Heterogeneity in CD41 Enriched Megakaryocytes After Targeted Therapy in Myeloproliferative Neoplasms
-
Treatment Patterns in Patients with Relapsed or Refractory NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US): Real-world Data Analysis